Xilio Therapeutics (XLO)

• Market cap: $58.6M
• 1 day: -3.47%
• 5 days: -1.22%
• 1 month: -0.34%
• 3 months: -1.44%
• 6 months: 3.61%
• Year to date: -5.32%
• 1 year: -16.27%
• 5 years: -96.03%
• 10 years: -96.03%
• Sector: Healthcare
• Industry: Biotechnology

About: Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.

Employees: 76